Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 26;17(1):61.
doi: 10.5334/gh.1141. eCollection 2022.

World Heart Federation Roadmap for Digital Health in Cardiology

Affiliations

World Heart Federation Roadmap for Digital Health in Cardiology

Jasper Tromp et al. Glob Heart. .

Abstract

More than 500 million people worldwide live with cardiovascular disease (CVD). Health systems today face fundamental challenges in delivering optimal care due to ageing populations, healthcare workforce constraints, financing, availability and affordability of CVD medicine, and service delivery. Digital health technologies can help address these challenges. They may be a tool to reach Sustainable Development Goal 3.4 and reduce premature mortality from non-communicable diseases (NCDs) by a third by 2030. Yet, a range of fundamental barriers prevents implementation and access to such technologies. Health system governance, health provider, patient and technological factors can prevent or distort their implementation. World Heart Federation (WHF) roadmaps aim to identify essential roadblocks on the pathway to effective prevention, detection, and treatment of CVD. Further, they aim to provide actionable solutions and implementation frameworks for local adaptation. This WHF Roadmap for digital health in cardiology identifies barriers to implementing digital health technologies for CVD and provides recommendations for overcoming them.

Keywords: digital health interventions for CVD; e-health; health system governance.

PubMed Disclaimer

Conflict of interest statement

Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic, Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).

Figures

The potential of digital health interventions for CVD. © World Heart Federation
Figure 1
The potential of digital health interventions for CVD. © World Heart Federation.
Selected roadblocks and solutions to implement digital health interventions, based on the WHO/ITU framework. © World Heart Federation
Figure 2
Selected roadblocks and solutions to implement digital health interventions, based on the WHO/ITU framework. © World Heart Federation.
NCD nurse using mPower Health CDSS in a government health facility, reproduced with permission from the Centre for Chronic Disease Control (CCDC), New Delhi, India
Figure 3
NCD nurse using mPower Health CDSS in a government health facility, reproduced with permission from the Centre for Chronic Disease Control (CCDC), New Delhi, India.
CONNECT smartphone application. Reproduced from NPJ Digit Med. 2020; 3. Redfern J, Coorey G, Mulley J, et al., A digital health intervention for cardiovascular disease management in primary care (CONNECT) randomized controlled trial
Figure 4
CONNECT smartphone application. Reproduced from NPJ Digit Med. 2020; 3. Redfern J, Coorey G, Mulley J, et al., A digital health intervention for cardiovascular disease management in primary care (CONNECT) randomized controlled trial.

References

    1. Burden G, Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76: 2982–3021. - PMC - PubMed
    1. Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396: 1223–1249. DOI: 10.1016/S0140-6736(20)30752-2 - DOI - PMC - PubMed
    1. Barber RM, Fullman N, Sorensen RJD, Bollyky T, McKee M, Nolte E, et al. Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: A novel analysis from the global burden of disease study 2015. Lancet. 2017; 390: 231–266. DOI: 10.1016/S0140-6736(17)30818-8 - DOI - PMC - PubMed
    1. Manne-Goehler J, Geldsetzer P, Agoudavi K, Andall-Brereton G, Aryal KK, Bicaba BW, et al. Health system performance for people withdiabetes in 28 low-and middle-incomecountries: A cross-sectional study of nationallyrepresentative surveys. PLoS Med. 2019; 16. DOI: 10.1371/journal.pmed.1002751 - DOI - PMC - PubMed
    1. Zhou B, Danaei G, Stevens GA, Bixby H, Taddei C, Carrillo-Larco RM, et al. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019; 394: 639–651. DOI: 10.1016/S0140-6736(19)31145-6 - DOI - PMC - PubMed

Publication types

MeSH terms